Stay updated on Pembrolizumab in Endometrial Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Endometrial Cancer Clinical Trial page.

Latest updates to the Pembrolizumab in Endometrial Cancer Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe webpage has undergone significant changes, including the removal of detailed study objectives and inclusion criteria for a clinical trial on pembrolizumab for recurrent endometrial cancer, while adding information about collaborators and a new revision number.SummaryDifference53%
- Check30 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and the date has changed from 2025-03-25 to 2025-01-31.SummaryDifference0.3%
- Check66 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check87 days agoChange DetectedThe page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
- Check94 days agoChange DetectedThe website has been updated with new entries for January 2025 and a revision to version 2.14.2, while previous entries from April 2024 and the earlier revision 2.14.1 have been removed.SummaryDifference0.8%
Stay in the know with updates to Pembrolizumab in Endometrial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Endometrial Cancer Clinical Trial page.